New treatments for AMD [6]

Ophthalmology

Volumn 113, Issue 1, 2006, Pages 160-161

  Spaide, Richard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB;

DRUG EFFECT; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PUBLICATION; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

APTAMERS, NUCLEOTIDE; HUMANS; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 29644440928     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2005.10.023     Document Type: Letter

References (9)

1. A.P. Schachat New treatments for age-related macular degeneration Ophthalmology 112 2005 531 532
2. Eyetech Pharmaceuticals, Pfizer, Inc. Dermatologic and Ophthalmic Drugs Advisory Committee meeting. Pegaptanib sodium injection (Macugen) [PowerPoint presentation]. 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/04/ slides/2004-4053S1_01_EyeTech-Main.ppt. Accessed May 27, 2005.
3. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 2004 2805 2816
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group Verteporfin in Photodynamic Therapy Study Group Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration TAP and VIP report no. 1 Am J Ophthalmol 136 2003 407 418
5. Eyetech Pharmaceuticals, Inc. Form S-1. Registration statement and prospectus summary for Macugen (pegaptanib sodium injection). Washington: United States Securities and Exchange Commission. 2004:46. Available at: http://www.sec.gov/Archives/edgar/data/1115285/000095012304006285/y97374sv1.htm. Accessed May 27, 2005.
6. N.E. Breslow Statistics in epidemiology the case-control study J Am Stat Assoc 91 1996 14 28
7. FDA Center for Drug Evaluation and Research. Medical Officer's review of NDA 21-756 - Macugen final label. 2004:13. Available at: http://www.fda.gov/ cder/foi/nda/2004/21-756_Macugen_medr.pdf. Accessed May 27, 2005.
8. C.D. De Angelis, J.M. Drazen, F.A. Frizelle Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors N Engl J Med 352 2005 2436 2438
9. R. Steinbrook Gag clauses in clinical-trial agreements N Engl J Med 352 2005 2160 2162